Leadless Pacemakers Market Report 2026

Leadless Pacemakers Market Overview

• Leadless Pacemakers market size has reached to $0.67 billion in 2025 • Expected to grow to $1.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.9% • Growth Driver: Heart Disease Trends Fueling Growth In The Leadless Pacemaker Market • Market Trend: Leadless Dual-Chamber Systems Transforming Cardiac Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leadless Pacemakers Market?

Leadless pacemakers refer to a type of cardiac pacing device designed to provide electrical stimulation to the heart without using traditional leads (wires). These self-contained devices eliminate the need for these leads, reducing the risk of lead-related complications such as infection, breakage, and displacement. The main types of leadless pacemakers are micra transcatheter pacing systems and others. The micra transcatheter pacing system (TPS) is a leadless pacemaker designed to provide pacing therapy for patients with bradycardia, a condition characterized by a slow or irregular heartbeat. The various pacing chambers include a single chamber and a dual chamber. These are used in various applications such as hospitals, specialty clinics, and others.

What Is The Leadless Pacemakers Market Growth Forecast?

The leadless pacemakers market size is expected to see rapid growth in the next few years. It will grow to $1.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to rising demand for minimally invasive cardiac therapies, technological advancements in battery and device longevity, increasing adoption of remote patient monitoring, expansion of electrophysiology centers, growing investment in next-generation cardiac devices. Major trends in the forecast period include growing adoption of leadless cardiac pacing systems, shift toward minimally invasive cardiac implant procedures, rising preference for devices with reduced infection risk, expansion of dual-chamber leadless pacemaker development, increasing integration of remote cardiac monitoring.

Global Leadless Pacemakers Market Segmentation

1) By Product Type: Ventricular Leadless Pacemakers, Atrioventricular (AV) Synchronous Leadless Pacemakers, Dual-Chamber Leadless Pacemaker Systems 2) By Fixation Mechanism: Passive Fixation, Active Fixation 3) By Indication: Bradycardia, Atrioventricular Block, Atrial Fibrillation with Slow Ventricular Response, Other Indications 4) By End User: Hospitals, Cardiac Specialty Clinics, Ambulatory Surgical Centers Subsegments: 1) By Ventricular Leadless Pacemakers: VVI-Mode Leadless Pacemakers, Rate-Responsive Ventricular Leadless Pacemakers (VVIR), Single-Module Ventricular Leadless Pacemakers 2) By Atrioventricular (AV) Synchronous Leadless Pacemakers: Accelerometer-Based AV Synchronous Leadless Pacemakers, Algorithm-Driven AV Synchrony Leadless Pacemakers, Single-Module AV Synchronous Leadless Pacemakers 3) By Dual-Chamber Leadless Pacemaker Systems: Modular Dual-Chamber Leadless Pacemaker Systems, Communicating Leadless Atrial and Ventricular Pacemaker Systems, Wireless Synchronized Dual-Chamber Leadless Pacemakers

What Are The Drivers Of The Leadless Pacemakers Market?

The increasing heart disease is expected to propel the growth of the leadless pacemaker market going forward. Heart diseases refer to a range of conditions that affect the heart's structure or function, leading to impaired blood flow, abnormal heart rhythms, or other cardiovascular complications. The rising heart diseases are due to population growth and aging, lifestyle factors, stress and inactivity, healthcare system challenges, and genetic and environmental factors. Leadless pacemakers offer significant advantages in managing certain heart diseases by providing effective pacing while reducing the risk of lead-related complications and offering a less invasive implantation procedure. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, there are expected to be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022. Therefore, increasing heart disease is driving the growth of the leadless pacemaker industry. The growing preference for minimally invasive procedures is expected to drive the growth in the leadless pacemaker market going forward. Minimally invasive procedures refer to medical interventions performed through tiny incisions or natural body openings using specialized instruments and imaging guidance to reduce tissue damage, pain, and recovery time while ensuring effective diagnostic or therapeutic outcomes. A growing preference for minimally invasive procedures is rising primarily due to their ability to reduce recovery time and postoperative discomfort, encouraging more patients and providers to choose these techniques over traditional open surgeries. Leadless pacemakers support minimally invasive procedures by eliminating the need for surgical pockets and transvenous leads, allowing implantation through a small catheter-based approach that reduces tissue disruption and speeds recovery. For instance, in March 2024, according to a report published by the American Society of Plastic Surgeons (ASPS), a US-based professional medical organization, total cosmetic minimally invasive procedures increased from 23,672,269 in 2022 to 25,442,640 in 2023, reflecting a 7% year-over-year growth. Therefore, the growing preference for minimally invasive procedures is driving the leadless pacemaker industry.

Key Players In The Global Leadless Pacemakers Market

Major companies operating in the leadless pacemakers market are Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, EBR Systems Inc., Cairdac, Imricor Medical Systems Inc., Osypka Medical GmbH, Shree Pacetronix Ltd., Lepu Medical Technology Co. Ltd., Terumo Corporation, MEDICO S.p.A., Vitatron Holding B.V., Oscor Inc., CathRx Ltd., Japan Lifeline Co. Ltd., Cardiac Pacemakers Inc., NVT AG

Global Leadless Pacemakers Market Trends and Insights

Major companies operating in the leadless pacemakers market are focusing on developing innovative products such as dual‑chamber systems to improve cardiac pacing efficiency and patient outcomes. A dual chamber system is a type of pacemaker that simultaneously monitors and stimulates both the atrium and the ventricle of the heart, helping to maintain proper timing between the upper and lower chambers, improve blood flow, prevent irregular heart rhythms, and enhance overall cardiac efficiency and patient quality of life. For instance, in July 2023, Abbott Laboratories, a US-based medical-device company, received US Food and Drug Administration (FDA) approval for its AVEIR DR dual‑chamber leadless pacemaker system, enabling two tiny devices one in the atrium and one in the ventricle to communicate beat-to-beat via its implant-to-implant (i2i) technology. By eliminating the need for transvenous leads, this system significantly reduces the risk of infection and mechanical complications while providing more physiologic pacing. As adoption of dual‑chamber leadless pacemakers grows, these innovations are expected to expand the patient population eligible for minimally invasive cardiac pacing and improve long-term clinical outcomes.

Regional Outlook

North America was the largest region in the leadless pacemakers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Leadless Pacemakers Market?

The leadless pacemakers market consists of sales of single-chamber leadless pacemakers, nanostim leadless pacemakers, dual-chamber leadless pacemakers, wireless cardiac resynchronization therapy (CRT) systems, and MRI-compatible leadless pacemakers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leadless Pacemakers Market Report 2026?

The leadless pacemakers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leadless pacemakers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.